Shenzhen Futian hospital for Rheumatic diseases, Futian District, #22 Nonglin Road, Shenzhen 518040, Guangdong, China.
Department of Orthopedics, the Eighth Affiliated Hospital of Sun Yat-sen University, Futian District, #3025Shennanzhong Road, Shenzhen 518040, Guangdong, China.
Biosci Rep. 2020 Feb 28;40(2). doi: 10.1042/BSR20191927.
The pathogenesis of reactive arthritis (ReA) has not been fully elucidated. In recent years, many researchers have confirmed that multiple cytokines are involved in the occurrence and development of ReA. Although ReA is self-limiting, it is still incurable for some patients who have no or a weak response to traditional drugs, such as non-steroidal anti-inflammatory agents, glucocorticoids and immunosuppressive agents. This is called refractory reactive arthritis. Currently, there is insufficient evidences for the treatment of refractory ReA with biological agents, though biological agents against cytokines have been developed over the past few years. This review summarizes the current development of clinical treatments of ReA with biological agents, which provides future investigations on refractory ReA with more evidence and references.
反应性关节炎(ReA)的发病机制尚未完全阐明。近年来,许多研究人员已经证实,多种细胞因子参与了 ReA 的发生和发展。虽然 ReA 是自限性的,但对于一些对传统药物(如非甾体抗炎药、糖皮质激素和免疫抑制剂)无反应或反应较弱的患者来说,它仍然是无法治愈的。这种情况被称为难治性反应性关节炎。目前,生物制剂治疗难治性 ReA 的证据不足,尽管近年来已经开发出针对细胞因子的生物制剂。本文综述了生物制剂治疗 ReA 的临床研究进展,为今后难治性 ReA 的研究提供了更多的证据和参考。